In more than 20 tumor types, especially in ACC, BLCA, LIHC, LUAD, PAAD, and UCEC (Supplementary Figure S7), patients with mutated TP53 tended to have higher ANLN expression levels compared to those with wild-type TP53. This evidence concerns the gene TP53 and adrenal cortex carcinoma.